Drug intelligence / Profile preview

IN-2403

Development stage: Preclinical
Lead developer: Indivumed
Modality: Small Molecules

Overview

IN-2403 is a preclinical small molecule therapeutic being developed by Indivumed for the treatment of colorectal cancer (CRC). The drug was identified through Indivumed's proprietary multi-omics platform, which leverages a large database of patient-derived samples to discover novel therapeutic targets. As of September 2025, IN-2403 is in the 'Hit to Lead' stage of development. While the specific biological target has not been publicly disclosed, the program is part of a pipeline focused on precision oncology and the identification of drivers in solid tumors.

Beyond the preview

Go deeper on IN-2403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN-2403.

Explore the full profile